Menu Search
Equities

Inhalation Sciences Sweden AB

ISAB:AKT

Inhalation Sciences Sweden AB

Actions
  • Price (SEK)1.81
  • Today's Change0.085 / 4.93%
  • Shares traded300.00
  • 1 Year change-54.52%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Inhalation Sciences Sweden AB grew revenues 43.55% from 12.19m to 17.50m. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -12.13m to -4.74m.
Gross margin86.29%
Net profit margin-25.36%
Operating margin-21.97%
Return on assets-20.53%
Return on equity-30.14%
Return on investment-29.23%
More ▼

Cash flow in SEKView more

In 2023, Inhalation Sciences Sweden AB increased its cash reserves by 325.50%, or 5.99m. Cash Flow from Financing totalled 9.73m or 55.58% of revenues. In addition the company used 3.74m for operations while cash from investing was breakeven.
Cash flow per share-0.1966
Price/Cash flow per share--
Book value per share0.7409
Tangible book value per share0.6602
More ▼

Balance sheet in SEKView more

Inhalation Sciences Sweden AB appears to have a strong balance sheet and has grown its cash reserves consistently over the last four years to total 7.83m. In fact, 0.29% of the value of Inhalation Sciences Sweden AB shares can be attributed to this cash.
Current ratio3.66
Quick ratio2.81
Total debt/total equity0.0683
Total debt/total capital0.0639
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.